Novo Nordisk A/S (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 128   

Articles published

NVO 54.90 +0.13 (0.24%)
price chart
Novo Nordisk A/S (ADR) Application For Insulin Drug Tresiba Accepted By FDA
Novo Nordisk A/S (ADR) (NYSE:NVO) has yet another victory to add to its long established success story in the diabetes market.
Novo Nordisk A/S (ADR) Shoots Up On Plans To Resubmit NDAs Of Tresiba And ...
Novo Nordisk A/S (ADR) (NYSE:NVO), the world's largest insulin-maker, announced Thursday its plans to resubmit New Drug Applications (NDAs) of its long-acting insulin candidate Tresiba and related drug Ryzodeg to the US Food and Drug Administration ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Resubmits Application for Approval of Its ...  WallStreet.org
Call Buyers Take Aim at Surging Novo Nordisk A/S (NVO)  Schaeffers Research (blog)
Novo Nordisk A/S (ADR) Anticipates Price Gains For Its Insulin Drugs Even As ...
Novo Nordisk A/S (ADR) (NYSE:NVO) is optimistic about the company's ability to charge high prices for its diabetes products this year and the next year, despite increased competition in the market from Sanofi SA (ADR) (NYSE:SNY) as well as other ...
Novo Nordisk A/S (ADR) (NYSE:NVO) Trying to Increase Market Share  WallStreet.org
Novo Nordisk A/S (ADR) Anti-Obesity Drug Approved By European Commission
Novo Nordisk A/S (ADR) (NYSE:NVO), has another victory to add to its success story: its obesity drug Saxenda has won marketing authorization from the European Commission as announced on Monday.
Form 6-K NOVO NORDISK AS For: Mar 23  StreetInsider.com
Novo Nordisk A/S (ADR) Price Target Update
Novo Nordisk A/S (ADR) (NYSE:NVO): The mean short term price target for Novo Nordisk A/S (ADR) (NYSE:NVO) has been established at $58.52 per share.
Novo Nordisk To Go Ahead With Russian Investment
The world's largest insulin-maker, Novo Nordisk A/S (ADR) (NYSE:NVO) is going ahead with its investment plans for Russia, even after the ruble's drastic fall.
Latest Updates on Novo Nordisk A/S (ADR) (NYSE:NVO)
The injectable drug is the second obesity treatment to be approved by the FDA this year; the first obesity-related treatment, approved in September, was Contrave, an oral medicine by Orexigen Therapeutics Inc. (NASDAQ:OREX).
Novo Nordisk (NVO) Searching For A New CEO  Bidness ETC
Related articles »  
CHMP Gives Positive Opinion On Novo Nordisk's Obesity Drug Saxenda
Yesterday Novo Nordisk A/S (ADR) (NYSE:NVO) said that it has received a positive verdict from the Committee for Medicinal Products for Human Use (CHMP), for its obesity drug Saxenda.
Novo Nordisk Gets Positive CHMP Opinion For Obesity Drug Saxenda  Nasdaq
Colgate-Palmolive Company (CL), Novo Nordisk A/S (ADR) (NVO) Among ...
The quantitative hedge fund Renaissance Technologies, formerly managed by billionaire Jim Simons, has been so successful that it has been partly responsible for prompting other funds to begin the process of looking into and setting up their own ...
Novo Nordisk (NVO) Wins FDA Nod For Weight-Loss Injection
Novo Nordisk A/S (ADR) (NYSE:NVO) announced Wednesday that the US Food and Drug Administration (FDA) has approved its experimental weight-loss injection, Saxenda, to treat obesity in adults.
Related articles »